Nonalcoholic fatty liver disease mortality may not be decreasing: A need for careful interpretation of GBD 2019 estimates of liver deaths
- PMID: 37437539
- DOI: 10.1016/j.cmet.2023.06.012
Nonalcoholic fatty liver disease mortality may not be decreasing: A need for careful interpretation of GBD 2019 estimates of liver deaths
Abstract
The Global Burden of Disease (GBD) data provide information on population health; however, careful understanding of the estimation methods and limitations of these data is critical. Herein, Paik et al. discuss the recent study by Chew and colleagues in the context of these limitations, highlighting how a worsening trend in NAFLD-liver mortality may have been underestimated in the analysis.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests Z.M.Y. has received research funding and/or serves as consultant to Intercept, Cymabay, Boehringer Ingelheim, BMS, GSK, NovoNordisk, AstraZeneca, Siemens, Madridgal, Merck, and Abbott.
Comment in
-
Response to Paik et al. on the disease burden of NAFLD.Cell Metab. 2023 Jul 11;35(7):1089-1090. doi: 10.1016/j.cmet.2023.05.012. Cell Metab. 2023. PMID: 37437540
Comment on
-
The global burden of metabolic disease: Data from 2000 to 2019.Cell Metab. 2023 Mar 7;35(3):414-428.e3. doi: 10.1016/j.cmet.2023.02.003. Cell Metab. 2023. PMID: 36889281
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical